SCHEMBL4496447

SCHEMBL4496447

O=C(Nc1nnc(C(=O)Nc2ccc(N3CCOCC3)c(F)c2)o1)c1ccc(Cl)cc1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 10/20 0.74
HTT P42858 5/20 0.63
KMT2A Q03164 5/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
LMNA P02545 3/20 0.63
MAPT P10636 3/20 0.63
MEN1 O00255 3/20 0.63
MAPK1 P28482 1/20 0.63
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
MAPKAPK2 P49137 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3544733 0.91 DGAT1 (0.75) DGAT1HTTKMT2ASMN1; SMN2LMNA
SCHEMBL13755344 0.85 DGAT1 (1.00) DGAT1HTTKMT2ASMN1; SMN2LMNA
SCHEMBL3540550 0.85 DGAT1 (0.78) DGAT1HTTKMT2ANPC1RAB9A
SCHEMBL3538069 0.83 DGAT1 (0.78) DGAT1HTTKMT2ASMN1; SMN2NPC1
SCHEMBL3540579 0.82 DGAT1 (0.82) DGAT1HTTKMT2ANPC1RAB9A
SCHEMBL3541332 0.81 DGAT1 (0.81) DGAT1HTTKMT2ANPC1RAB9A
SCHEMBL4497793 0.81 DGAT1 (0.82) DGAT1HTTSMN1; SMN2LMNAMAPT
SCHEMBL3545114 0.81 DGAT1 (0.75) DGAT1HTTKMT2ASMN1; SMN2LMNA
SCHEMBL3542139 0.80 DGAT1 (0.83) DGAT1HTTKMT2ANPC1RAB9A
SCHEMBL3540411 0.80 DGAT1 (1.00) DGAT1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US claimed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP claimed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO claimed
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP disclosed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT2, GPR119, DGAT1 DGAT1 3/4885HTT 2402/4885KMT2A 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.